Celldex Therapeutics (id:5262 CLDX)
27.02 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 10:58:31 AM)
Exchange closed, opens in 1 day 22 hours
2.62 USD (2.62%)
13.72 USD (13.72%)
-10.35 USD (-10.35%)
-27.73 USD (-27.73%)
-5.16 USD (-5.16%)
1,117.12 USD (1,117.12%)
-91.40 USD (-91.40%)
-91.71 USD (-91.71%)
About Celldex Therapeutics
Market Capitalization 1.79B
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
| Headquarters (address) |
Perryville III Building Hampton 08827 NJ United States |
| Phone | 908 200 7500 |
| Website | https://www.celldex.com |
| Employees | 160 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | CLDX |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 22.93 - 53.18 |
| Market Capitalization | 1.79B |
| P/E trailing | -9.25 |
| P/E forward | -8.37 |
| Price/Sale | 179.69 |
| Price/Book | 2.28 |
| Beta | 1.59 |
| EPS | -2.58 |
| EPS United States (ID:6, base:3400) | 24.26 |